A new, highly sensitive cell therapy was able to wipe out three different kinds of solid tumors in mice, an important advance in an area where CAR-T cells have long struggled. But significant ...
California-based immunotherapy company 3T Biosciences has appointed Rebeca Villarreal-Barragan as head of clinical operations ...
Houston, Texas and Tuebingen, Germany, April 23, 2025 – Immatics N.V. (IMTX) (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and ...
Researchers hope to undertake clinical studies in multiple cancers, including ovarian cancer, glioblastoma, and others.
Immatics N.V., a clinical-stage biopharmaceutical company, announced that it will present data on its lead cell therapy candidate, IMA203 TCR T-cell therapy targeting PRAME, at the upcoming 2025 ASCO ...
Completed enrollment of Cohort C in the Phase 1 ALLOHA™ trial; patients to be treated with commercial-ready manufacturing process ...
SINGAPORE and GUANGZHOU, China, Sept. 14, 2025 /PRNewswire/ -- Lion TCR, a clinical-stage biotechnology company pioneering T-cell receptor (TCR)-based therapies, today announced that it has received ...
Jefferson Health oncologist Jennifer Johnson had exhausted all the standard treatment options for her 49-year-old patient with esophageal cancer, who was likely to die within months. Surgery, ...
Advances in cell and gene therapy have led to U.S. Food and Drug Administration approved adoptive cell therapies to treat hematological malignancies and solid tumors. There is great enthusiasm in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results